rocuronium + neostigmine + atropine

This pharmacological regimen refers to a specific anesthetic protocol used to induce and subsequently reverse a moderate level of neuromuscular blockade during surgical procedures. The regimen involves the administration of **rocuronium**, a non-depolarizing neuromuscular blocking agent (NMBA) that acts as a competitive antagonist at nicotinic acetylcholine receptors in the neuromuscular junction to facilitate surgery. To reverse the blockade at the end of the procedure, **neostigmine**, an acetylcholinesterase inhibitor, is administered to increase the concentration of acetylcholine at the synapse, thereby displacing the rocuronium. **Atropine**, a muscarinic antagonist, is co-administered with neostigmine to mitigate the parasympathetic side effects, such as bradycardia and increased secretions, that result from systemic acetylcholinesterase inhibition. This specific combination was utilized as the 'Standard of Care' control arm in clinical trials conducted by the **University of Medicine and Pharmacy at Ho Chi Minh City** to evaluate the quality of recovery in patients undergoing elective laparoscopic cholecystectomy.

Other names

Moderate neuromuscular blockModerate neuromuscular blockadeModerate neuromuscular block protocol